Ascendis Pharma
ASND
ASND
158 hedge funds and large institutions have $5.45B invested in Ascendis Pharma in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 60 increasing their positions, 55 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
17% less capital invested
Capital invested by funds: $6.54B → $5.45B (-$1.09B)
18% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 33
38% less funds holding in top 10
Funds holding in top 10: 13 → 8 (-5)
Holders
158
Holding in Top 10
8
Calls
$43.5M
Puts
$26.7M
Top Buyers
| 1 | +$381M | |
| 2 | +$45.5M | |
| 3 | +$43.3M | |
| 4 |
FAM
Fred Alger Management
New York
|
+$31.3M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$31.1M |
Top Sellers
| 1 | -$192M | |
| 2 | -$117M | |
| 3 | -$82.7M | |
| 4 |
Artisan Partners
Milwaukee,
Wisconsin
|
-$55.5M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
-$37.6M |